- Home
- PWM vs COEP Comparison
PWM vs COEP Comparison
Compare PWM & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- COEP
- Stock Information
- Founded
- PWM 2018
- COEP 2017
- Country
- PWM Hong Kong
- COEP United States
- Employees
- PWM N/A
- COEP N/A
- Industry
- PWM
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PWM
- COEP Health Care
- Exchange
- PWM Nasdaq
- COEP Nasdaq
- Market Cap
- PWM 38.5M
- COEP 86.0M
- IPO Year
- PWM 2023
- COEP N/A
- Fundamental
- Price
- PWM $1.22
- COEP $15.29
- Analyst Decision
- PWM
- COEP
- Analyst Count
- PWM 0
- COEP 0
- Target Price
- PWM N/A
- COEP N/A
- AVG Volume (30 Days)
- PWM 2.8M
- COEP 66.5K
- Earning Date
- PWM 02-13-2026
- COEP 11-12-2025
- Dividend Yield
- PWM N/A
- COEP N/A
- EPS Growth
- PWM N/A
- COEP N/A
- EPS
- PWM N/A
- COEP N/A
- Revenue
- PWM $142,570.00
- COEP $263,555.00
- Revenue This Year
- PWM N/A
- COEP N/A
- Revenue Next Year
- PWM N/A
- COEP N/A
- P/E Ratio
- PWM N/A
- COEP N/A
- Revenue Growth
- PWM N/A
- COEP N/A
- 52 Week Low
- PWM $0.31
- COEP $2.31
- 52 Week High
- PWM $2.70
- COEP $19.19
- Technical
- Relative Strength Index (RSI)
- PWM 86.81
- COEP 49.85
- Support Level
- PWM $0.49
- COEP $14.90
- Resistance Level
- PWM $0.93
- COEP $16.17
- Average True Range (ATR)
- PWM 0.12
- COEP 1.17
- MACD
- PWM 0.05
- COEP -0.30
- Stochastic Oscillator
- PWM 74.87
- COEP 11.94
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.